Abstract
Throughout the last several decades, vaccination has been key to prevent and eradicate infectious diseases. However, many pathogens (e.g., respiratory syncytial virus [RSV], influenza, dengue, and others) have resisted vaccine development efforts, largely because of the failure to induce potent antibody responses targeting conserved epitopes. Deep profiling of human B cells often reveals potent neutralizing antibodies that emerge from natural infection, but these specificities are generally subdominant (i.e., are present in low titers). A major challenge for next-generation vaccines is to overcome established immunodominance hierarchies and focus antibody responses on crucial neutralization epitopes. Here, we show that a computationally designed epitope-focused immunogen presenting a single RSV neutralization epitope elicits superior epitope-specific responses compared to the viral fusion protein. In addition, the epitope-focused immunogen efficiently boosts antibodies targeting the palivizumab epitope, resulting in enhanced neutralization. Overall, we show that epitope-focused immunogens can boost subdominant neutralizing antibody responses in vivo and reshape established antibody hierarchies.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antibodies, Monoclonal, Humanized / chemistry
-
Antibodies, Monoclonal, Humanized / immunology
-
Antibodies, Neutralizing / biosynthesis*
-
Antibodies, Neutralizing / genetics
-
Antibodies, Viral / biosynthesis*
-
Antibodies, Viral / genetics
-
Cloning, Molecular
-
Computer-Aided Design
-
Epitopes / chemistry*
-
Epitopes / immunology
-
Escherichia coli / genetics
-
Escherichia coli / metabolism
-
Female
-
Gene Expression
-
Genetic Vectors / chemistry
-
Genetic Vectors / metabolism
-
Immunization / methods
-
Immunogenicity, Vaccine
-
Mice
-
Mice, Inbred BALB C
-
Nanoparticles / administration & dosage
-
Nanoparticles / chemistry
-
Palivizumab / chemistry
-
Palivizumab / immunology
-
Receptors, Antigen, B-Cell / chemistry
-
Receptors, Antigen, B-Cell / genetics
-
Receptors, Antigen, B-Cell / immunology*
-
Recombinant Fusion Proteins / administration & dosage
-
Recombinant Fusion Proteins / chemistry*
-
Recombinant Fusion Proteins / genetics
-
Recombinant Fusion Proteins / immunology
-
Respiratory Syncytial Virus Vaccines / administration & dosage
-
Respiratory Syncytial Virus Vaccines / biosynthesis
-
Respiratory Syncytial Virus Vaccines / genetics
-
Respiratory Syncytial Viruses / immunology*
-
Structural Homology, Protein
-
Viral Fusion Proteins / administration & dosage
-
Viral Fusion Proteins / chemistry*
-
Viral Fusion Proteins / genetics
-
Viral Fusion Proteins / immunology
Substances
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neutralizing
-
Antibodies, Viral
-
Epitopes
-
Receptors, Antigen, B-Cell
-
Recombinant Fusion Proteins
-
Respiratory Syncytial Virus Vaccines
-
Viral Fusion Proteins
-
motavizumab
-
Palivizumab
Grants and funding
FS was supported by the Swiss initiative for systems biology (SystemsX.ch). BEC was supported by the European Research Council (Starting grant - 716058) and the Swiss National Science Foundation (Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; 310030_163139). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.